Well, this should be a depressing read -- notably because the UK and the US are both terrible when it comes to data protection, but the UK appears to be getting a pass. So much for 'adequacy'.

A few initial thoughts on the Draft Decision on UK Adequacy: https://t.co/ncAqc93UFm

The decision goes into great detail about the state of the UK surveillance system, and notably, "bulk acquisition" of data, and I think I get their argument. /1
For one, while the UK allows similar "bulk powers," it differs from the US regime both in terms of proportionality, oversight, and even notice. Some of this came about after the Privacy International case in 2019 (Privacy International) v Investigatory
Powers Tribunal [2019]) /2
Whereas, other bits were already baked in by virtue of the fact that the Human Rights Act is a thing (This concept doesn't exist in the US; rather we hand-wave about the Constitution and Bill of Rights, and then selectively apply it) /3
For example, UK bulk surveillance (I'm keeping this broad, but the draft policy breaksk it down), substantially limits collection to three agencies: MI5, MI6, and GHCQ). By contrast, it's a bit of a free-for-all in the US, where varying policies /4
and a general lack of oversight, mean that foreign and domestic law enforcement (NSA, CIA, FBI, DHS, LLE) basically do bulk collection of US and non-US citizens on the regular. And only a handful of these efforts go through any sort of judicial review (e.g., the FISC). /5
By contrast, UK surveillance has multiple levels of oversight - including from the ICO (Sec. 2.6 of the draft), the Judicial Data Protection Panel (Sec. 2.6.3), the Investigatory Powers Commissioner (Sec. 3.3.3.2), and Parliament (Sec. 3.2.3.4) /6
(I'm skipping a few, because there's a lot of oversight!). One thing that also exists is direct rights of redress by data subjects -- primarily through the ICO (Sec. 3.2.4). Unlike in the US, where the FISC is fairly hollow and a rubber-stamp, the ICO actually /7
seems to have some enforcement teeth. (Sec. 3.2.6, 3.2.3.1), and there's a right of redress against the ICO if they become too rubber-stampy (Sec. 2.6.4). But there's also process through the Investigatory Powers Tribunal (3.3.4.2), and the European Court of Human Rights /8
This is, by contrast, to the nearly non-existent redress rights in the US noted in the Schrems II decision. Hell, data subjects can't even find out if they've been surveilled due to gag orders tied to CLOUD Act and FISA orders. /9
Finally, there's collection and retention obligations that (AFAIK) don't exist in the US. (Sec. 3.3.1.1.1), with strict periods of collection (E.g., 3.3.1.1.2 for telecom data, 12 months for communications data).

Honestly, there are way more safeguards /10
than I originally realized.

That said, I'm saying the UK is the best system, or that it's all roses and sunshine for data subjects. But on a preliminary level, I think the EC's draft proposal is well thought out and provides clear insight /11
As to why the concerns of Schrems II are easier to address/satisfy within the UK regime, compared to that of the US.

That said, I'm no expert. What am I missing? What didn't I consider?
@threadreaderapp unroll pls

More from Internet

A thread of resources for aspiring & new Product Managers:

(should also be useful for Eng, Design, Data Science, Mktg, Ops folks who want to get better at PM work or want to build more empathy for your PM friends ☺️)

(oh, and pls also share *your* favorite resources below)

👇🏾

1/

Product Management - Start Here by @cagan
(hard to go wrong if you start with Marty Cagan’s

2/

Tips for Breaking into PM by @sriramk
(I’ve recommended this thread in my DMs more often than any other thread, by a pretty wide


3/

Top 100 Product Management Resources by @sachinrekhi
(well-categorized index so you can focus on whatever’s most useful right

4/

Brief interruption.

It’s important to understand your preferred learning style and go all in on that learning style (vs. struggling / procrastinating as you force a non-preferred learning

You May Also Like

Recently, the @CNIL issued a decision regarding the GDPR compliance of an unknown French adtech company named "Vectaury". It may seem like small fry, but the decision has potential wide-ranging impacts for Google, the IAB framework, and today's adtech. It's thread time! 👇

It's all in French, but if you're up for it you can read:
• Their blog post (lacks the most interesting details):
https://t.co/PHkDcOT1hy
• Their high-level legal decision: https://t.co/hwpiEvjodt
• The full notification: https://t.co/QQB7rfynha

I've read it so you needn't!

Vectaury was collecting geolocation data in order to create profiles (eg. people who often go to this or that type of shop) so as to power ad targeting. They operate through embedded SDKs and ad bidding, making them invisible to users.

The @CNIL notes that profiling based off of geolocation presents particular risks since it reveals people's movements and habits. As risky, the processing requires consent — this will be the heart of their assessment.

Interesting point: they justify the decision in part because of how many people COULD be targeted in this way (rather than how many have — though they note that too). Because it's on a phone, and many have phones, it is considered large-scale processing no matter what.
@EricTopol @NBA @StephenKissler @yhgrad B.1.1.7 reveals clearly that SARS-CoV-2 is reverting to its original pre-outbreak condition, i.e. adapted to transgenic hACE2 mice (either Baric's BALB/c ones or others used at WIV labs during chimeric bat coronavirus experiments aimed at developing a pan betacoronavirus vaccine)

@NBA @StephenKissler @yhgrad 1. From Day 1, SARS-COV-2 was very well adapted to humans .....and transgenic hACE2 Mice


@NBA @StephenKissler @yhgrad 2. High Probability of serial passaging in Transgenic Mice expressing hACE2 in genesis of SARS-COV-2


@NBA @StephenKissler @yhgrad B.1.1.7 has an unusually large number of genetic changes, ... found to date in mouse-adapted SARS-CoV2 and is also seen in ferret infections.
https://t.co/9Z4oJmkcKj


@NBA @StephenKissler @yhgrad We adapted a clinical isolate of SARS-CoV-2 by serial passaging in the ... Thus, this mouse-adapted strain and associated challenge model should be ... (B) SARS-CoV-2 genomic RNA loads in mouse lung homogenates at P0 to P6.
https://t.co/I90OOCJg7o